Cargando cotizaciones...
Previsión
El precio objetivo medio de los analistas es de 32,80 € (+27.233,33 %). La mediana es de 32,80 € (+27.233,33 %).
| Comprar |
4 |
| Mantener |
1 |
| Vender |
0 |
Noticias Ir al feed de noticias
BiomX acquires 10% of M.E.A. Testing Systems and secures option to buy majority
BiomX purchases 324,573 shares (10% diluted) of M.E.A. Testing Systems for $50,000 and 1,300,000 restricted common shares, and receives an exclusive option until June 30, 2028 to acquire the remaining approximately 78.9% at a price of two times net revenue or four times EBITDA for fiscal year 2027. Closing is contingent on approval of an NYSE American listing application and the execution of a license agreement that grants BiomX exclusive worldwide rights to MEA technologies, including drone testing solutions. The transaction takes place despite strained liquidity at BiomX (debt-funded free cash flow of -$23m; financial health score 1.45) and is accompanied by the appointment of Roy Timor-Rousso as chief business officer to strengthen focus on defense and security technologies. » Más en de.investing.com
BiomX completes acquisition of AI security software provider Zorronet
BiomX has completed the full takeover of Zorronet from Water.io, expanding its portfolio with AI-driven command-and-control software that links video analytics, drones, sensors and IoT into an operational picture. Zorronet holds contracts with the Israel Defense Forces and Israel Railways and serves customers such as Elbit Systems, addressing defense, security and rescue segments. BiomX has a market capitalization of around USD 20 million and a current ratio of 2.7, but faces challenges from rapid cash burn despite a high gross margin. » Más en de.investing.com
BiomX reports quarterly EPS of -21.39 USD and reduces annual loss
BiomX released figures for the quarter ended 31 December 2025 with earnings per share (EPS) of -21.39 USD versus -21.85 USD a year earlier. For the fiscal year the company reported a loss per share of -22.19 USD after -27.93 USD in the prior year. » Más en finanzen.net
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 290,9 mil | - |
| Beneficio bruto | 84,99 mil | 134,31 % |
| Beneficio neto | -3,31 M | 35,47 % |
| EBITDA | -3,34 M | 31,02 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 1,21 M € |
Número de acciones | 10,15 M |
Máximo/mínimo de 52 semanas | 10,61 € - 0,10 € |
| Dividendos | No |
Beta | 1,37 |
Ratio P/E | -0,01 |
Ratio PEG | 0,00 |
Ratio P/B | 0,13 |
Ratio P/S | 4,23 |
Perfil de la empresa
| Nombre | BIOMX INC. NEW Aktie |
| CEO | Michael Oster |
| Empleados | 20 |
Descubrir activos
Los accionistas de BIOMX INC. NEW Aktie también invierten en los siguientes activos




